In NETU037, moved Tuesday June 26, we are advised by the company that the second graph, tenth line should read "...after its first patent expiry in Europe (UK and Germany) in 2003 (2005 in the United States)..." rather than "...after its patent expiry in 2003..." as originally issued. Complete corrected release follows:
Impending Patent Expiration of Merck & Co.'s Simvastatin Will Shift Hyperlipidemia Market Dynamics. Decision Resources Study Evaluates the Impact of the Next Generation of Lipid-Modifying Agents.
WALTHAM, Mass., June 26 /PRNewswire/ -- Hyperlipidemia is a new study from Decision Resources, Inc., that examines factors that will influence the market for current and emerging drugs to treat this condition over a 2000-2010 forecast period.
In the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), the leading agents for the treatment of hyperlipidemia are the HMG-CoA reductase inhibitors (statins). While the statins will continue to dominate the lipid-lowering market through the forecast period, the impending patent expiration of simvastatin (Merck & Co.'s Zocor), one of the current market leaders, will shift marketplace positioning. Atorvastatin (Pfizer/Parke-Davis's Lipitor) will become the market leader until the launch of the new "superstatin" rosuvastatin (AstraZeneca's Crestor) in 2002. We believe that Merck, in order to maintain sales of simvastatin after its first patent expiry in Europe (UK and Germany) in 2003 (2005 in the United States), will put a significant amount of effort into marketing a therapy combining simvastatin and Schering Plough's cholesterol absorption inhibitor ezetimibe. This particular combination therapy, which addresses LDL lowering via two mechanisms, is set to fill a niche-market need for treatment of severe hyperlipidemia when aggressive statin therapy is not tolerated.
The strongest factor limiting the size of the current market is that hyperlipidemia is primarily regarded not as a disease but as one of several factors that contribute to the risk of developing CHD. Because lipid-lowering is seen as a preventive treatment, the market is particularly price sensitive. Consequently, we believe the total number of patients receiving treatment for hyperlipidemia will peak during our forecast period, and we expect that pressure on physicians to prescribe generics will remain a factor in all of the major markets. In addition, the number of prevalent cases of hyperlipidemia in the major markets will not increase dramatically enough over the forecast period to become a sales growth driver.
Hyperlipidemia offers invaluable market intelligence for companies developing drugs to treat this condition. This study is part of Cardium, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org (e-mail).
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,